Wei et al. demonstrated that miR-183 is a potential candidate for immunotherapy, as it showed anti-glioma efficacy by modulating the immune system: miR-183 overexpression in human CD4+ T cells lead to decreased CTLA-4, PD-1, and Forkhead box protein 3 (FoxP3) expression and in vivo miR-183 treatment of GL261 gliomas in immune-competent mice showed tumor regression, which could not be observed in immune-incompetent mice or after CD4+ or CD8+ T cell depletion. Here, FOXP3 is linked to glioma.